AbbVie Inc. (ABBV) vs Visa Inc. (V)

See how AbbVie Inc. and Visa Inc. differ across market data and performance, so you can decide which asset best fits your strategy.

$256.42
NYSE
AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.
View Full Page
$379.37
NYSE
Visa Inc. is the world’s largest payment processor. In fiscal 2025, the company handled nearly $17 trillion in total payment volume. Visa operates in more than 200 countries and territories and processes transactions in over 160 currencies. Its network is capable of handling more than 65,000 transactions per second.
View Full Page

Key Metrics Comparison

AbbVie Inc.ABBV
Market Cap
$453.124B
Price
$256.42
24h Change
+0.37%
24h Volume
$4.24M
Employees
57,000
Shares Outstanding
1,768,169,012
Visa Inc.V
Market Cap
$708.302B
Price
$379.37
24h Change
-0.58%
24h Volume
$6.72M
Employees
34,100
Shares Outstanding
1,659,709,932

Category Performance

Visual comparison across key categories. Ring fill represents relative strength or share between the two assets.

Market Share

Share of combined market cap

Market Share
ABBV
39.0%
V
61.0%

Volume Share

Share of combined 24h volume

Volume Share
ABBV
38.7%
V
61.3%

24h Performance

Price change over last 24 hours

24h Performance
ABBV
0.37%
V
-0.58%
Price Comparison
AbbVie Inc.
Visa Inc.